Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the "Company"), effective June 1, 2026. Ms. Bachrodt's resignation was not as a result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices or on any matter relating to the Company's financial reporting.

Misbah Tahir, the Company's Chief Financial Officer, will be designated principal accounting officer following Ms. Bachrodt's departure.